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Open access under the ElsPatients with oral cancer can have high psychological distress levels, but the effects of stress-related hor-
mones on oral cancer cells and possible mechanisms underlying these relationships are unknown. In this
study, we have investigated the effects of stress-related hormones on interleukin-6 (IL-6) secretion and
proliferation of oral squamous cell carcinoma (OSCC) cells. The effects of norepinephrine (NE), and cor-
tisol were studied in SCC9, SCC15, and SCC25 cells and effects of isoproterenol in SCC9 and SCC25 cells.
Real-time PCR studies revealed constitutive b1- and b2-adrenergic receptors (b-ARs) expression in the
SCC9, SCC15, and SCC25 cells. The results showed that NE and isoproterenol signiﬁcantly enhanced
IL-6 mRNA expression and protein production in supernatants of SCC9 and SCC25 cells. Physiological
stress levels of NE and isoproterenol (10 lM) at 1 h elicited the most robust IL-6 increase. Regarding
IL-6 secretion, 10 lM NE induced a 5-fold increase at 1 h, 3.7-fold increase at 6 h, and 3.2-fold at 24 h
in SCC9 cells. These effects were blocked by the b-adrenergic antagonist propranolol, supporting a role
for b-ARs in IL-6 secretion. The effects of cortisol varied according to the hormone concentration. Phar-
macological concentrations of cortisol (1000 nM) inhibited IL-6 production by SCC9 and SCC25 cells. Cor-
tisol dose that simulates stress conditions (10 nM) tended to increase IL-6 expression in SCC9 cells.
Hormonal doses that simulate stress conditions (10 lMNE, at 6 h in SCC9 and SCC15 cells and 10 nM cor-
tisol, at 48 h in SCC15 cells) stimulated increased cell proliferation. Treatment of SCC9 cells with IL-6 neu-
tralizing ab (10 lg/mL) partially inhibited NE-induced proliferation. Finally, 20 OSCC biopsies were shown
to express b1- and b2-ARs. These ﬁndings suggest that stress hormones can affect oral cancer cells behavior.
 2010 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
A growing number of studies have shown that hormonal and
immune alterations resulting from chronic stress and other behav-
ioral conditions may inﬂuence cancer development and progres-
sion (Reiche et al., 2004; Thaker et al., 2007; Antoni et al., 2006;
Lillberg et al., 2003). Chronic stress is associated with dysregula-
tion of the hypothalamic–pituitary–adrenal (HPA) axis, with con-
sequent increase in the production of the hormone cortisol, and
elevated levels of norepinephrine (NE) and epinephrine (E), which
are catecholamines released from the adrenal medulla and the
neurons of the sympathetic nervous system (SNS) (Thaker et al.,
2007; Glaser and Kiecolt-Glaser, 2005).
Neurohormonal products derived from chronic stress may re-
duce the natural killer cell cytotoxicity by inhibiting the responseenter, School of Dentistry of
onifácio St. 1193, CEP 16015-
233.
ernabé).
evier OA license. of cells to certain cytokines such as interferon-gamma (IFN-c)
and interleukin-2 (IL-2) (Kiecolt-Glaser and Glaser, 1999; Esterling
et al., 1996). Stress hormones also have the ability to act directly on
tumor cells and to deregulate the production of cytokines, chemo-
kines, and growth factors that are related to cancer development
and progression (Reiche et al., 2004; Antoni et al., 2006; Ardestani
et al., 1999). For example, studies on ovarian cancer have shown
that catecholamines enhance the expression of substances such
as vascular endothelial growth factor (VEGF) and matrix metallo-
proteinases (MMPs), which are known to inﬂuence tumor progres-
sion (Lutgendorf et al., 2003; Sood et al., 2006; Yang et al., 2008).
Other investigations have demonstrated that the neurohormonal
products derived from chronic stress inﬂuence skin (Saul et al.,
2005), breast (Ben-Eliyahu et al., 1991), lung (Melamed et al.,
2005), and colon (Lointier et al., 1992) cancer progression.
Interleukin-6 (IL-6) is a cytokine that plays an important role in
angiogenesis and tumoral progression (Heikkilä et al., 2008). The
head and neck squamous cell carcinoma (HNSCC) cell line secrete
IL-6 (Chakravarti et al., 2006), and a high level of this cytokine has
been detected in the saliva and blood of patients with HNSCC
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scribed that IL-6 stimulates cell proliferation (Chakravarti et al.,
2006) and bone invasion of OSCC cells (Okamoto et al., 2000). High
IL-6 levels in OSCC tissue and plasmahave also been associatedwith
recurrence, lymphnode involvement, and a poor prognostic survival
(Duffy et al., 2008; Nagata et al., 2003). IL-6 has been directly related
to chronic stress. Individuals who experience emotional stress dis-
play high IL-6 circulating levels (Kiecolt-Glaser et al., 2003).
Recently, it has been shown that NE can increase IL-6 expression
in malignant melanocytes (Yang et al., 2009) and human ovarian
carcinoma cells (Nilsson et al., 2007), thereby contributing to the
development of these tumors.
There are few studies investigating the inﬂuence of stress hor-
mones on HNSCC. Recently, the presence of b-adrenergic receptors
(b-AR) for NE and E has been identiﬁed in oral (Shang et al., 2009)
and esophagus cancer (Liu et al., 2008) cell lines. These investiga-
tions also showed that the proliferation of these cell lines is stim-
ulated by NE and E, respectively. Nevertheless, there is no evidence
that IL-6 expression in oral cancer can be inﬂuenced by stress hor-
mones. In this study, we have evaluated the effects of stress-
related hormones on IL-6 expression and proliferation of OSCC
cells, and evidence that OSCC biopsies express b-ARs is provided.2. Materials and methods
2.1. Cell culture and hormone treatment
The OSCC-derived cell lines SCC9, SCC15, and SCC25 were used
in the evaluation of the effects of stress hormones. The cell lines
were kindly provided by Dr. Ricardo Della Coletta (School of Den-
tistry, State University of Campinas, Piracicaba, São Paulo, Brazil).
These cells were maintained and propagated in a 1:1 mixture of
Dulbecco’s modiﬁed Eagle’s medium (DMEM) and Ham’s F12 med-
ium (DMEM/F12; Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS), 100 lg/mL penicillin, 100 lg/
mL streptomycin, and 0.1% gentamicin, at 37 C, in 5% CO2
humidiﬁed atmosphere. Experiments were carried out with 80%
conﬂuent cultures. SCC9, SCC15, and SCC25 cells were seeded in
24-well plates (1.0  105 cells per well) and cultured for 24 h in
serum-reduced medium (0.1% FBS). The following hormones were
tested: NE (Calbiochemical Co, La Jolla, CA), cortisol (Sigma–
Aldrich, St. Louis, MO) and isoproterenol (Sigma–Aldrich, St. Louis,
MO), a b-adrenergic agonist. The cells SCC9 and SCC25 were then
treated with NE or isoproterenol at 0, 0.1, 1, and 10 lM, or cortisol
at 0, 1, 10, 100, and 1000 nM. These concentrations were used in
the subsequent experiments. The cells SCC15 were treated with
NE and cortisol. For blocking experiments, 1 lM propranolol was
added to the cell cultures 1 h before addition of 10 lMNE. Cell-free
supernatants and cells were collected at 1, 6, and 24 h, and kept at
 80 C until the assays were performed. The hormone concentra-
tions employed were deﬁned by taking the physiological levels
that usually reaching in the tumor microenvironment. NE basal cir-
culating levels range between 10 pM and 1 nM (Sood et al., 2006),
and studies have suggested that stress increases these levels to
approximately 100 nM, and they may reach 10 lM in the microen-
vironment of some types of tumors (Antoni et al., 2006; Sood et al.,
2006). The concentrations of 10 and 100 nM cortisol reﬂect similar
levels to those found in stress conditions, and higher concentra-
tions (1000 nM) simulate pharmacological doses of glucocorticoids
(Miller and O’Callaghan, 2002).2.2. Real-time PCR assessment of IL-6 gene expression
Quantitative real-time reverse transcription-PCR (RT-PCR) was
used to assess the IL-6 gene expression in SCC9, SCC15, andSCC25 cells treated with stress hormones. Total RNA from cell lines
was isolated with TRIzol, following the manufacturer’s instructions
(Invitrogen Life Technologies, Carlsbad, CA). The RNA concentra-
tion was measured by spectrophotometry. First strand cDNAs were
synthesized using 1 lg of total RNA and Superscript II RNase H
reverse transcriptase (Invitrogen Life Technologies). IL-6 mRNA
levels were measured by means of the SYBR Green system and
ampliﬁed in the Stepone Real-Time PCR system (Applied Biosys-
tems). The housekeeping gene b-actin was employed as internal
positive control. The primers were as follows: b-actin (forward,
50-TGGATCAGCAAGCAGGAGTATG-30; reverse, 50 GCATTTGCGGTG-
GACGAT-30) and IL-6 (forward, 50-AGGGCTCTTCGGCAAATGTA-30;
reverse, 50-GAAGGAATGCCCATTAACAACAA-30). Primers were
drawn using the Primer Express software (Applied Biosystems).
Reactions were carried out using a volume of 20 lL, and each sam-
ple was run in duplicate. The PCR thermal cycle conditions used in
the experiments were those recommended by the manufacturer.
The IL-6 mRNA expression levels in each sample were normalized
to the b-actin mRNA level. The results were analyzed using the
comparative threshold cycle (CT) method. Results were presented
on fold increase of the IL-6 mRNA expression in cells treated with
hormones as compared to untreated cells.
2.3. Determination of IL-6 protein expression
The total IL-6 protein concentrations in the supernatants of the
SCC9 and SCC25 cells treated with stress hormones were deter-
mined. Serum-reduced conditioned medium from cultures of oral
cancer cells was collected at 1, 6, and 24 h following exposure to
NE, isoproterenol, or cortisol. Quantiﬁcation of serum IL-6 levels
was accomplished by the quantitative sandwich enzyme immuno-
assay technique (ELISA) (R&D Systems, Minneapolis, MN) following
the manufacture’s protocol. The resulting color was read in a spec-
trophotometer set to the wavelength of 450 nm.
2.4. b1- and b2-AR expression in OSCC cell lines
To assess whether the SCC9, SCC15, and SCC25 cell lines express
mRNA for b1- and b2-AR, real-time PCR assay was performed as
described previously. The utilized primers were b1 (forward,
50-GCGTGTGATGCATCTTTAGATTTT-30; reverse, 50- CCTAACCCACC
CATCTTCCA-30) and b2 (forward, 50-TTGAAGGCCTATGGGAATGG-
30; reverse, 50-TCCACTCTGCTCCCCTGTGT-30). Primers were drawn
using the Primer Express software. The b-actin gene was used as
endogenous control.
2.5. MTT cell proliferation assay
OSCC cells SCC9 and SCC15 were seeded in 96-well plates
(1.0  103 per well) and grown in 100 lL 10% FBS-supplemented
DMEM/F12 medium. After 20% conﬂuence had been reached, cells
were cultured for 24 h in serum-reduced medium (0.1% FBS). Cells
were treated with NE or cortisol. Blocking experiments were per-
formed with propranolol (1 lM added 1 h before addition of
10 lM NE). The MTT solution was carried out by dissolving 5 mg
of MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide] (Sigma) in 1 mL of PBS, followed by ﬁltration and steril-
ization in Millipore ﬁlter 0.22 lm. The MTT solution (100 lL)
diluted 10 in serum-reduced medium (0.1%) was added to each
well after 6, 24, and 48 h of hormone treatment. The cells remained
for 4 h at 37 C and 5% CO2 humidiﬁed atmosphere. The MTT solu-
tion was aspirated, and isopropanol (100 lL per well) was added.
The plate was then stirred for 30 min at room temperature, to sol-
ubilize the blue formazan crystals that stained the mitochondria.
Colorimetric quantiﬁcation was determined by spectrophotometry
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in six replicates and were repeated three times.2.6. Effects of IL-6 neutralizing ab on NE-induced proliferation
To evaluate whether NE-induced OSCC proliferation is mediated
by IL-6, anti-IL-6 ab (R&D Systems, Minneapolis, MN) was
employed to neutralize the action of IL-6. Brieﬂy, after SCC9 cells
had reached 20% conﬂuence, cells were cultured for 24 h in ser-
um-reduced medium (0.1% FBS). Then, the SCC9 cells were pre-
treated with IL-6 neutralizing ab (1 and 10 lg/mL) for 30 min prior
to the addition of NE (10 lM). Cells were further incubated for 6 h,
and proliferation was evaluated by MTT assay.
2.7. b1- and b2-AR expression in OSCC biopsies, oral leukoplakia
biopsies, and normal oral mucosa
To assess whether OSCC cells express b1- and b2-AR, 20 tumor
specimens were collected from patients with OSCC who had not re-
ceived any treatment yet. All the OSCC cases had the diagnosis con-
ﬁrmed histologically. Once removed from the surgery site, the
specimens were washed in saline solution, placed in a tube con-
taining TRIzol reagent (Invitrogen Life Technologies, Carlsbad,
CA), and immediately stored in liquid nitrogen. For comparative
analysis, 17 specimens of oral leukoplakia (considered a precursor
lesion of OSCC) and 15 samples of normal oral mucosa were col-
lected and stored following the same protocol. The samples were
then thawed and ground in TRIzol with an electric homogenizer.Fig. 1. Human OSCC cell lines were stimulated with norepinephrine (A, SCC9; B, SCC25; a
collected 1 h (square), 6 h (triangle), or 24 h (oval) after stimulus. Total RNA was isolated
percentage of IL-6 mRNA expression of stimulated cells relative to control (non-stimul
⁄⁄⁄P 6 0.001.The total RNA was then extracted, cDNA was synthesized, and
real-time PCR assay was performed as previously described.
2.8. Statistical analysis
Data were checked for normality, and statistical analysis was
performed by one-way analysis of variance (ANOVA) followed by
the Bonferroni’s multiple-comparison test. P values <0.05 were
considered signiﬁcant.
3. Results
3.1. Adrenergic stimulation upregulates IL-6 gene expression in OSCC
cells
In all the evaluated times (1, 6, and 24 h), treatment of SCC9,
SCC15, and SCC25 cells with physiological stress levels of NE
(10 lM) elevated IL-6 mRNA expression. Maximum IL-6 expression
peaked 1 h after stimulation with 10 lM NE, leading to an increase
of 501.5 ± 34.8%, 317.1 ± 32.65%, and 237.7 ± 37.6% in IL-6 mRNA
expression in SCC9 (p < 0.001), SCC15 (p < 0.05), and SCC25 cells
(p < 0.05), respectively (Fig. 1A–C). A smaller but signiﬁcant
enhancement in IL-6 mRNA levels in the SCC9 and SCC25 cell lines
was also observed after 6 h of stimulation with NE, which did not
continue after 24 h (Fig. 1A and B). The synthetic b-adrenergic
receptor agonist isoproterenol also induced a signiﬁcant rise in
IL-6 mRNA expression in SCC9 and SCC25 cells (SCC15 cells were
not tested for isoproterenol). Speciﬁcally, after 1 h of treatment
of SCC9 cells with 1 and 10 lM isoproterenol, IL-6 RNAm levelsnd C, SCC15) and isoproterenol (0.1, 1, or 10 lM) (D, SCC9 and E, SCC25). Cells were
, and real-time PCR was used to quantify IL-6 RNA. Values are presented in points as
ated cells – 0 lM or 0 nM), which was set as 100%. Bars, SE. ⁄P 6 0.05; ⁄⁄P 6 0.01;
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respectively (Fig. 1D). As in the case of SCC9 cells, after 1 h,
10 lM isoproterenol induced a signiﬁcant increase in IL-6 mRNA
production by SCC25 cells (267.2 ± 43.5%; p < 0.05). However, after
longer periods, higher IL-6 mRNA levels were observed with 1 lM
isoproterenol, where only the increase after 6 h was signiﬁcant
(194.1 ± 5.8%; p < 0.05) (Fig. 1E).
3.2. Adrenergic stimulation increases IL-6 protein levels in culture
supernatants
IL-6 protein levels were measured in supernatants of the SCC9
and SCC25 cells. Production of IL-6 protein by SCC9 cells at the
three tested times was enhanced compared to the production by
SCC25 cells. For example, the mean basal levels of IL-6 production
by SCC9 and SCC25 cells at 1 h with no stimulation were
58.63 ± 3.42 pg/mL and 3.11 ± 1.06 pg/mL, respectively. The basal
level of IL-6 production by SCC9 and SCC25 cells with no stimula-
tion were detectable at 1 h and increased over the time period
examined (Figs. 2 and 3). For both cell lines, physiological stress
levels of NE (10 lM) elicited the most robust IL-6 increase. Maxi-
mum elevations in IL-6 occurred at 1 h of incubation. As depicted
in Fig. 2A, stimulation of SCC9 cells with 10 lM NE for 1 h pro-
duced 301.3 ± 3.45 pg/mL of IL-6 protein, resulting in an approxi-
mately 5-fold increase (p < 0.001) compared to the control. After
6 h, 10 lM NE induced a 3.7-fold increase, whereas after 24 h aFig. 2. Adrenergic stimulation increases IL-6 secretion by OSCC cells. Human OSCC c
isoproterenol (C and D) (0.1, 1, or 10 lM). Supernatants were collected 1 h, 6 h, or 24 h aft
triplicate determinations of the IL-6 concentration. ⁄P 6 0.05; ⁄⁄P 6 0.01; ⁄⁄⁄P 6 0.001.3.2-fold enhancement in IL-6 production (p < 0.001) was detected.
As for SCC25 cells, treatment with 1 lM NE for 1 h produced a 2.1-
fold increase in IL-6 production, and 10 lM NE induced an eleva-
tion of approximately 3-fold (Fig. 2B). For both SCC9 and SCC25
cells, a maximum IL-6 rise was observed after 6 h in the presence
of 10 lM isoproterenol. The mean basal level of IL-6 secretion by
SCC9 cells after 6 h was 83.18 ± 3.23 pg/mL. The IL-6 levels in-
creased to 272.3 ± 12.42 pg/mL after treatment with 1 lM isopro-
terenol (p < 0.001), and to 487.1 ± 15.27 pg/mL after treatment
with 10 lM isoproterenol (p < 0.001) (Fig. 2C). The patterns of
the IL-6 increase in SCC25 cells after isoproterenol stimulation
were similar to those found in SCC9 cells, except for the stimulus
with 0.1 lM isoproterenol after 24 h, which reduced IL-6 levels
(but this result was not signiﬁcant) (Fig. 2D).
3.3. The effects of cortisol on IL-6 expression in OSCC cells
The pattern of IL-6 mRNA expression after treatment with cor-
tisol was distinct from that found for NE and isoproterenol. The
effects of cortisol varied according to the hormone concentration.
In SCC9 cells, in general, higher concentrations of cortisol (100
and 1000 nM) determined lower IL-6 mRNA and protein produc-
tion. For 1000 nM cortisol, a dose that is approximately equiva-
lent to pharmacological levels of glucocorticoid, there was a
signiﬁcant decrease in IL-6 mRNA expression at all the tested
periods. A larger suppression in IL-6 mRNA expression and IL-6ell lines (SCC9 and SCC25) were stimulated with norepinephrine (A and B) and
er the stimulus, and IL-6 was measured by ELISA. Data represent the mean (±SEM) of
Fig. 3. Cortisol inﬂuences IL-6 expression and secretion by tumor cells. SCC9, SCC25, and SCC15 cells were stimulated with cortisol (1, 10, 100, or 1000 nM). Cells were
collected 1 h (square), 6 h (triangle), or 24 h (oval) after stimulus and real-time PCR was used to quantify IL-6 RNA (A, C, and E). Supernatants were collected 1, 6, or 24 h after
the stimulus, and IL-6 was measured by ELISA (B and D). ⁄P 6 0.05; ⁄⁄P 6 0.01; ⁄⁄⁄P 6 0.001.
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cortisol at 24 h. This treatment reduced IL-6 mRNA expression
by 298 ± 1.9% compared to the control (p < 0.01) (Fig. 3A) and
induced a 2.7-fold decrease in IL-6 protein levels (p < 0.001)
(Fig. 3B). In contrast, after 1 h, 10 nM cortisol (simulating physi-
ological stress levels) promoted increase IL-6 mRNA expression
(129% compared to control) (Fig. 3A) and protein levels
(Fig. 3B) in SCC9 cells, but these changes did not reach signiﬁ-
cance. These cortisol effects were blocked by glucocorticoid
inhibitor Meﬁpristone (data not shown). SCC25 cells did not ex-
hibit a signiﬁcant response to cortisol treatment. Speciﬁcally,
SCC25 cells treated with 1000 nM cortisol at 6 h produced
292.2 ± 17.40 pg/mL of IL-6, resulting in a 1.25-fold decrease
compared to the control (p < 0.05) (Fig. 3D). In these same cells,
lower IL-6 mRNA levels were detected at 1 h with 100 nM corti-
sol (131.1 ± 0.03% compared to the control) and 1000 nM cortisol
(152.1 ± 2.7%), while an increase in IL-6 mRNA levels took place
at 24 h using 10 nM cortisol (138 ± 12.96%) and 100 nM cortisol
(147 ± 28.75%), but these results were not signiﬁcant (Fig. 3C).
Similar results were found in SCC15 cells, inwhich lower cortisol
concentrations (1 and 10 nM) did not determine large variations in
IL-6mRNA levels, whereas high concentrations simulating pharma-
cological concentrations (e.g., 1000 nM) decreased IL-6 expression
(but these results were not signiﬁcant) (Fig. 3E).3.4. Stress hormones increase OSCC cell proliferation
To examine the effects of stress hormones on OSCC cell prolifer-
ation, SCC9 and SCC15 cells were treated with different doses of NE
and cortisol, and cell proliferation was assayed by MTT at 6, 24, and48 h. The SCC25 cell line was not assayed by MTT because it did not
respond well (absence of cell growth) to culture in serum-reduced
medium (0.1% FBS). Stimulation of SCC9 and SCC15 cells with
physiological NE stress levels (10 lM) induced an enhancement
of 170 ± 17.7% (p < 0.05) and 124 ± 13.7% (p < 0.05) in cell prolifer-
ation at 6 h compared with non-treated cells, respectively (Fig. 4A).
These NE-induced effects of SCC9 and SCC15 cells were not signif-
icant at subsequent times (24 and 48 h) (data not shown). In SCC9
cells, treatment with pharmacological levels of cortisol (1000 nM)
produced at later time point (48 h) a rise of approximately
200 ± 36.1% in cell proliferation (p < 0.05) (Fig. 4B). Cortisol doses
that simulate stress conditions (10 nM) induced at 48 h an increase
in cell proliferation in SCC9 (non-signiﬁcant) (Fig. 4B) and in SCC15
cells (135 ± 17.5%; p < 0.05) (Fig. 4B). There was no signiﬁcant in-
crease in the cell proliferation index after 6 and 24 h of stimulus
with cortisol (data not shown).3.5. Regulation of IL-6 expression and OSCC cell proliferation by stress
hormones requires b-ARs activation
Real-time PCR assays conﬁrmed that SCC9, SCC15, and SCC25
cells express mRNA for b1- and b2-AR (Fig. 5A). To determine
whether the increase in IL-6 expression was mediated through
b-adrenergic receptors, the cell lines were pre-treated with a non-
speciﬁc b antagonist (propranolol), at the time point of maximum
mRNA IL-6 expression (10 lMNE at 1 h). Propranolol pretreatment
inhibited NE-induced IL-6 mRNA expression in the three cell lines
investigated (Fig. 5B). Next, whether the increase in cell prolifera-
tion induced by NE was also mediated by b-ARs was assessed. SCC9
cells were treated with propranolol before stimulation with 10 lM
Fig. 4. Stress hormones increase OSCC cell proliferation. The human OSCC cell lines
SCC9 and SCC15 were stimulated with 0.1, 1, and 10 lM norepinephrine or with 1,
10, 100, and 1000 nM cortisol, and MTT cell proliferation assays were determined at
6, 24, and 48 h. The non-stimulated cells (0 lM or 0 nM) were set as 100%, and the
treated cells were determined relatively to non-stimulated cells. Signiﬁcant results
were found with NE at 6 h (A) and cortisol at 48 h (B). Bars represent the
mean ± SEM of six replicates, and the assays were performed in triplicate. ⁄P 6 0.05.
Fig. 5. (A) b1-AR and b2-AR RNA expression in the SCC9, SCC15, and SCC25 cell
lines. (B) IL-6 RNA expression is regulated through the b-AR. Human OSCC lines
(SCC9, SCC15, and SCC25) were stimulated with NE (10 lM) in the presence or
absence of the b-blocker propranolol (PROP) (1 lM). Propranolol was added 1 h
before the NE stimulus. Cells were collected 1 h after the NE stimulus, total RNA
was isolated, and real-time PCR was used to quantify IL-6 RNA. Data are presented
as the mean fold increase in IL-6 RNA expression relative to non-stimulated cells.
Bars represent means ± SEM. ⁄P 6 0.05; ⁄⁄⁄P 6 0.001. (C) Cell proliferation is b-AR-
dependent and anti-IL-6 ab partially inhibited the increase NE-induced cell
proliferation. For the inhibition experiments, propranolol (Prop) at 1 lM was
added 1 h before stimulus with 10 lM NE in SCC9 cells and IL-6 neutralizing ab (1
and 10 lg/mL) for 30 min prior to the stimulus. MTT cell proliferation assay
were determined at 6 h. Bars represent means ± SEM. ⁄P 6 0.05: 10 lM NE
group compared to control group (NE 0); ⁄⁄P 6 0.05: 10 lM NE + 1 lM Prop group
compared to 10 lM NE group; #P 6 0.05: 10 lM NE + anti-IL-6 (10 lg/mL) group
compared to 10 lM NE group.
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b-ARs produced signiﬁcant decrease in NE-induced cell prolifera-
tion, showing that this event is b-AR-dependent (Fig. 5C). This
decreasing in NE-induced cell proliferation after b-ARs inhibition
also was found in the SCC15 cells (results not shown).
3.6. Effects of IL-6 neutralizing ab on NE-induced proliferation
Since NE may stimulate IL-6 production by OSCC, whether NE-
induced OSCC proliferation is mediated by IL-6 was subsequently
tested. To this end, anti-IL-6 ab was used to neutralize the action
of IL-6 in SCC9 cells. As illustrated in Fig. 5C, treatment of SCC9
cells with 10 lg/mL of anti-IL-6 induced signiﬁcant inhibition of
NE-induced proliferation (p < 0.05). Anti-IL-6 in lower concentra-
tion (1 lg/mL) was not able to inhibit NE-induced proliferation
(Fig. 5C). Recombinant IL-6 increased SCC9 cell proliferation (data
not shown).
3.7. OSCC biopsies express b1- and b2-ARs
To determine the clinical relevance of our results, expression of
b1- and b2-ARs mRNAs were examined in 20 tumor specimens ofOSCC and compared with the expression in 17 specimens of oral
leukoplakia and 15 specimens of normal oral mucosa. Clinical char-
acteristics of patients from whom samples were obtained are sum-
marized in Table 1. b1- and b2-AR mRNAs were expressed in all 20
cases of OSCC. Of the 17 cases of leukoplakia, ﬁve were negative for
b1-AR and one was negative for b2-AR. Of the 15 specimens of nor-
mal mucosa, three did not express b1-AR and one was negative for
Table 1
Clinical characteristics of patients from whom samples were collected for evaluation
of mRNA expression for b1- and b2-AR by real-time PCR.
Clinical
Characteristics
Normal mucosa
(n = 15)
Leukoplakia
(n = 17)
OSCC
(n = 20)
Mean age (years) 62.2 (±8.36) 56.5 (±8.31) 60.25 (±11.22)
Range 40–79 42–82 43–80
Gender: n (%)
Male: n (%) 7 (47) 8 (47) 15 (75)
Female: n (%) 8 (53) 9 (53) 5 (15)
Sample site: n (%)
Floor of mouth 2 (13.3) 2 (11.8) 4 (20)
Gum 1 (6.7) 1 (5.9) 0 (0)
Tongue 2 (13.3) 3 (17.6) 4 (20)
Buccal mucosa 3 (20) 4 (23.5) 2 (10)
Hard palate 1 (6.7) 3 (17.6) 2 (10)
Alveolar ridge 4 (26.7) 2 (11.8) 4 (20)
Retromolar area 2 (13.3) 2 (11.8) 4 (20)
Tobacco use: n (%)
No 2 (13) 1 (5.9) 3 (15)
Yes 13 (87) 16 (94.1) 17 (85)
Alcohol consumption: n (%)
No 13 (86.7) 11 (64.7) 5 (8.8)
Yes 2 (13.3) 6 (35.3) 15 (35.4)
Clinical stage: n (%)
I – – 2 (10)
II 4 (20)
III 4 (20)
IV 10 (50)
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levels in OSCC specimens was 2.7-fold higher compared to normal
mucosa (p < 0.05), while in specimens of leukoplakia the expres-
sion was 1.6-fold higher (p > 0.05) (Fig. 6A). In contrast, b2-AR
mRNA mean expression was lower in leukoplakia compared to
normal mucosa and OSCC, but these results were not signiﬁcant
(Fig. 6A). The b-AR expression for each studied case can be better
seen in Fig. 6B and C.
4. Discussion
This study provides strong evidence that OSCC cells are inﬂu-
enced by neurohormonal mediators. The results demonstrated that
stress-related mediators (NE and isoproterenol) can enhance the
production of the pro-angiogenic cytokine IL-6 in human OSCC cell
lines. IL-6, originally identiﬁed as a B-cell growth factor, is pro-
duced by many cell types, including T-cells, macrophages, and
stromal cells. As seen in this study, OSCC cells are also capable of
producing IL-6, and basal levels are already detectable at 1 h. Se-
creted cytokine products, including IL-6, are available to interact
with cellular receptors; thus, they are able to exert paracrine or
autocrine effects. The concentrations of IL-6 secreted by OSCC cells
in this study, even by non-stimulated cells, are clearly within the
range expected to have biological activity. This activity is related
to autocrine growth stimulation of cancer cells (Hodge et al.,
2005) and could explain the non-stimulated increase in IL-6 ob-
served over the time period. Previous studies on melanoma (Yang
et al., 2009) and ovarian cancer cells (Nilsson et al., 2007) have
shown that IL-6 expression is upregulated via adrenergic stimula-
tion. Enhanced IL-6 production after NE treatment has also been
reported in myocytes (Briest et al., 2003) and human pancreatic
duct epithelial cells (Chan et al., 2008).
The NE and isoproterenol concentrations that determined max-
imum increase in IL-6 expression were within the levels that
would be produced from stress-related catecholamine secretion
(10 lM). Maximum elevations in IL-6 occurred at an early time(1 h), giving evidence of fast metabolism of adrenergic mediators
by OSCC cells. Nilsson et al. (2007) found that maximum increases
in IL-6 expression in ovarian carcinoma cells occurred only after
6 h of incubation with NE. Nilsson’s results after 3 h of treatment
of these same cells with NE showed just a minimum rise in IL-6
production. These data indicate that distinct tumors may have var-
iable sensitivity to catecholamines. The responses to NE were med-
iated by b-adrenergic receptors, whereas the b1- and b2-ARs
antagonist propranolol inhibited the NE-dependent upregulation
of IL-6 expression and protein release. This inhibition reached con-
trol levels in SCC15 and SCC25 cells and was partial in SCC9 cells,
indicating that other receptors can be involved in the SCC9 cell
activation during the NE-induced IL-6 production.
To our knowledge, this is the ﬁrst study showing that IL-6
expression and production in OSCC cells can be upregulated by
NE. The activation of the IL-6 complex is related to growth stimu-
lation of OSCC cells (Chakravarti et al., 2006). Moreover, high IL-6
production in tumor cells and plasma of patients with OSCC has
been associated with recurrence, regional metastasis, and poor sur-
vival (Duffy et al., 2008; Nagata et al., 2003). As a result, upregu-
lated IL-6 production in response to NE found in this study can
be a way for stress-related OSCC progression. It has also been
found that NE treatment increase the expression of other sub-
stances that contribute to angiogenesis (such as VEGF) in nasopha-
ryngeal carcinoma tumor cells, an EBV-associated malignant tumor
(Yang et al., 2006), and multiple myeloma-derived cells (Yang
et al., 2008).
Similarly to what happens in terms of IL-6 expression, treat-
ment with NE at physiological stress levels (10 lM) induced
SCC9 and SCC15 cell proliferation. Furthermore, IL-6 neutralizing
ab partially inhibited the NE-induced proliferation in SCC9 cells,
indicating a possible pathway among NE/IL-6/cell growth in OSCC
cells. The NE-induced SCC9 and SCC15 cell proliferation was med-
iated by b-adrenergic receptors and was signiﬁcant at 6 h, com-
pared to 24 and 48 h. The effects of b-adrenergic agonists on
malignant cell proliferation has been reported for several tumors,
including lung (Schuller et al., 1999), pancreas (Askari et al.,
2005), breast (Cakir et al., 2002), and gastric (Shin et al., 2007) can-
cers, all of which are adenocarcinomas. Studies investigating the
inﬂuence of catecholamines on human HNSCC cell proliferation,
as in our case, are still scarce. Liu et al. (2008) have demonstrated
that epinephrine stimulates esophageal squamous cell carcinoma
cell proliferation. This effect occurred via b-AR-dependent transac-
tivation of the extracellular signal-regulated kinase/cyclooxygen-
ase-2 pathway. Recently, Shang et al. (2009) have reported that
the OSCC cell line TCa8113 expresses b2-AR and presents NE-
induced proliferation, an effect that was also inhibited by propran-
olol. However, the authors presented no data concerning the
expression of the b1-receptor subtype. Here, constitutive expres-
sion of both b1- and b2-ARs in the three studied OSCC cell lines
has been demonstrated. Collectively, the results obtained by us
and by Shang et al. (2009) provide evidence that catecholamines
such as NE may play an important role in the progression of oral
cancer.
Effects of cortisol on IL-6 expression differ according to the hor-
mone dose. At different times, cortisol at a concentration compat-
ible with physiological stress levels in humans (10 nM) enhanced
IL-6 expression in SCC9, SCC15, and SCC25 cells, but these results
were not signiﬁcant. In contrast, cortisol concentrations closer to
pharmacological levels (1000 nM) promoted reduction in IL-6
expression at all analyzed time points in SCC9 and SCC15 cells.
These data suggest the possibility of cortisol have a dual role on
IL-6 expression in OSCC cell, in which doses that simulate physio-
logical stress levels (e.g., 10 nM) could have a proinﬂammatory
effect, while pharmacological doses inhibit the proinﬂammatory
cytokine IL-6. Inhibitory effects of glucocorticoids on the
Fig. 6. (A) b1-AR and b2-AR mRNA expression levels in specimens of human OSCC tumors (n = 20), human leukoplakia (n = 17), and normal human mucosa (n = 15). Each bar
represents the mean of the relative quantiﬁcation (RQ) of the b1-AR and b2-AR mRNA expression concerning the normal mucosa. ⁄P < 0.05, OSCC group compared with
healthy controls (normal mucosa) for b1-AR. (B and C) Individual representation of each patient according to their b1-AR (C) or b2-AR (B) mRNA expression.
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previously (Hasan et al., 2003; Yano et al., 2006). Nevertheless, in
these studies the cortisol was generally tested at pharmacological
concentrations (1000 nM or more). Lutgendorf et al. (2003) also
found different effects of cortisol on VEGF in ovarian carcinoma
cells, depending on the hormone dose. In line with our results on
IL-6, pharmacological doses of cortisol inhibited VEGF secretion,
while cortisol simulating physiological stress levels (10 nM) in-
duced signiﬁcant increase in VEGF. Although some types of non-
steroidal anti-inﬂammatory drugs (NSAIDs) cause antiproliferative
effects and induce apoptosis in HNSCC cell lines (Thurnher et al.,
2001; Pelzmann et al., 2004), it seems that the effects of glucocor-
ticoids on the growth of these cells are not as clear. For example,
previous experiments with a high dose of hydrocortisone(3000 nM) did not reveal relevant effects on the HNSCC cell prolif-
eration rate (Thurnher et al., 2001). Our ﬁndings showed that
10 nM cortisol increased the number of SCC15 cells after 48 h of
treatment, while doses of 1000 nM increase the number of SCC9
cells after the same time period. As observed in the case of cyto-
kines expression regulation, this result may suggest that the corti-
sol effect on the cell cycle proteins may be dependent on the
hormone levels. Further studies are necessary to evaluate which
underlying mechanisms are activated in OSCC cells after variations
of the systemic and tissue levels of cortisol in response to chronic
and acute stress conditions.
In addition to conﬁrming that OSCC cell lines express b1- and
b2-AR, we have also demonstrated that these receptors are
expressed in specimens of OSCC, oral leukoplakia, and normal oral
582 D.G. Bernabé et al. / Brain, Behavior, and Immunity 25 (2011) 574–583mucosa. The b-adrenergic receptors are members of the large
family of G protein-coupled receptors (GPCR), and their activation
involves protein-tyrosine-kinase-activated pathways, as well as
cyclic-adenosine-monophosphate (cAMC)-linked pathways. It has
been shown that several types of cancer express b-AR, which
may affect proliferation and migration as well as induce metastasis
(Askari et al., 2005; Cakir et al., 2002; Shin et al., 2007). b1-AR
expression in OSCC and oral leukoplakia specimens has not yet
been reported. Quantitatively, the mean b1-AR expression level
in OSCC was approximately 3- and 2-fold those encountered in
the normal mucosa and leukoplakia, respectively. These ﬁndings
suggest that the changes in epithelial and mesenchymal cells dur-
ing oral carcinogenesis can be accompanied by modiﬁcations in
b1-AR expression. Moreover, b1-adrenergic receptor agonists, such
as NE, could determine more pronounced effects in neoplastic
tissues compared to normal tissues. b2-AR expression in OSCC
biopsies has been previously analyzed by Shang et al. (2009).
Immunohistochemistry analysis showed that 67.7% of OSCC cases
were positive for b2-AR protein expression, while only 20% of adja-
cent normal mucosa specimens were positive for b2-AR staining
(Shang et al., 2009). However, b1-AR expression was not evaluated.
In our cases, only one specimen of normal mucosa was negative for
b2-AR, and there was no expressive difference in its expression
when tumor and normal mucosa specimens were compared. This
distinct result in terms of b2-AR expression obtained by us and
Shang et al. may be due to the use of different methods. In real-
time PCR assay other cells of the tumor microenvironment that
also express b-ARs in addition to epithelial cells are also included
in the analysis.
Previous studies have shown that patients with oral cancer can
have high psychological distress levels (Kugaya et al., 2000; Chen
et al., 2009). The effects of stress-related hormones on oral cancer
cells are still poorly understood. Although this study has limita-
tions because it is composed mainly of in-vitro assays, the results
reveal that stress-related mediators, mainly NE at concentration
compatible with physiological stress levels in humans, can
upregulate IL-6 expression and induce OSCC cell proliferation.
These ﬁndings provide one of the ﬁrst evidences that stress
hormones may act directly on OSCC cells and possibly affect tumor
progression.
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